腾盛博药-B：截至2026年6月30日止六个月之中期业绩公告

Brii Biosciences Limited騰盛博藥生物科技有限公司2137 2026630 2026630 •20266301,770.8202512311,941.0170.28.8% •202663019.5202563028.18.630.6%7.9•202663098.32025630117.018.716.0%HBV2•202663052.6202563058.25.69.6%•202663030.330.5•2026630101.02025630148.847.832.1% 騰盛博藥HBVRNA H B V20262bENSURE732bENRICHENHANCEENSUREENRICHENHANCEBRII-179ENRICHENHANCE2026 HBVRNABRII-5395(HCC)mRNA騰盛博藥RNABRII-5395mRNARNARNA2026騰盛博藥 HBV 2,163,3132,323,369 2026630 1. 騰盛博藥20171282021713 34 2. 202663020251231 202611 9797 11 3. 2026630382,766,00020251231381,604,000288,782,00020251231298,021,00093,984,0002025123183,583,000 4. 5. 630202620259483402,9242,415 6. 7. 63020262025 20252026630 20252026630 8. 9. 10. 30 0303160619090 騰盛博藥RNAHBV 2026HBV2bENSURE2bENRICHENHANCEBRII-179 HBVRNA BRII-5395(HCC)mRNA1騰盛博藥RNABRII-5395mRNARNARNA2026騰盛博藥 RNA HBV HBVHBV (1)騰盛博藥Vir Biotechnologyelebsirantobevibart (2)Vir BiotechnologyHDVelebsirantobevibart3 (3)騰盛博藥soralimixin騰盛博藥soralimixin HBV HBV2bENSUREENRICHENHANCEBRII-179 R N ABRII-5395OpenBenchAI 2026630RNA2029 HBV 2 bE N S U R E2 bE N R I C HENHANCEHBVHBVBRII-179HBVelebsiranHBVsiRNA BRII-179 BRII-179HBVPre-S1Pre-S2SHBVBTBRII-179 BRII-1792bENSUREENRICHENHANCEHBV 2bENSURE1-3PEG-IFNαelebsiranPEG-IFNα4BRII-179HBsAg 202652026EASLENSURE14 •elebsiranPEG-IFNαHBsAgPEG-IFNα •BRII-179-HBsBRII-179HBV 2bENRICHENHANCEBRII-179HBV ENRICHelebsiranPEG-IFNαBRII-17920267 •EOTBRII-1793527HBsAg42.9% (42/98)40.0% (20/50)ENSURE4BRII-17941.9% (13/31)HBsAgBRII-179 •ENRICHHBsAg(1000-3000 IU/mL)ENSURE4HBsAgBRII-179 ENHANCEA-1BRII-179elebsiranPEG-IFNαENHANCEA-2PEG-IFNα24BRII-179elebsiran24elebsiranPEG-IFNα2b20267 •EOTENHANCEA-1ENSURE23HBsAgENSURE23HBsAg29.7% (11/37)HBsAg25.5% (25/98)PEG-IFNα10.2% (5/49)HBsAg •ENHANCEA-2EOTHBsAg22.5% (18/80)PEG-IFNα ENSUREENRICHENHANCE 2026ENRICHENHANCE 20268191ENHANCEHBsAgENHANCEA-2HBsAg ElebsiranTobevibart ElebsiranAlnylam Pharmaceuticals, Inc.HBVsiRNAHBV RNAHBVHDVElebsiranHBV2020VirBiotechnologyelebsiran TobevibartHBsAgHBVHDVTobevibartVir BiotechnologyFcHBsAgXencorXtend™Tobevibart2022Vir Biotechnologytobevibart •Vir BiotechnologyECLIPSEelebsirantobevibart(CHD)ECLIPSE 1ECLIPSE 32026ECLIPSE 12027ECLIPSE 2ECLIPSE 3 RNA ADME/DMPKCMC BRII-5395騰盛博藥mRNAHBV(HCC) •2026812BRII-5395HCCBRII-5395PD-1VEGFHCC •mRNABRII-5395RNA BRII-5395mRNARNARNA RNA2026 SoralimixinBRII-693MDRsoralimixinSoralimixinMDR 20257soralimixinsoralimixin •20266soralimixinI •FDAsoralimixinFDA HIV HIV •BRII-753NRTTIEFdANCEBRII-753HIV •BRII-732NCEEFdAHIVEFdANRTTIHIVBRII-7321HIV 2026416Brii Biosciences Offshore Limited(Judicial Arbitration and Mediation Services, Inc.)Vir Biotechnology, Inc. 202641620265222026630 2026660202661610% Zhi HongDavid MargolisBrian A. JohnsEllee de Groot 202663098.3 RNA ENSUREENRICHENHANCE3ENRICH2026elebsiran3 RNARNA 2026630 1. 202563028.18.6202663019.57.9 2. 20256300.230.3202663030.5 3. 2025630117.018.7202663098.3202563049.913.1202663036.8202563065.75.7202663060.0HBV2 4. 202563058.25.6202663052.6202563033.88.1202663025.71.80.9 5. 2026630202512311,941.01,770.8 6. (95,936)(115,328) 7. 202620256301231 (1)(2) (1) (2)100% 8. 2026630 2026630 2026630166.2 9. 20266302026630 10. 202663020251231 11. 202663052.7%30.8%16.3%0.2% 12. 2026630802026630 202663062.5202563083.721.2 13. 202171326.14 2023324202532120263192026630 2027 20266302025 C1C.2.1 C.2.1Zhi HongZhi HongZhi HongZhi Hong 202663012,723,500 •24102026630 Grace Hui TangGrace Hui Tang 20266302026630 (www.hkexnews.hk)(www.briibio.com)2026630 BTDCDEC1騰盛博藥騰盛博藥EASLEFdANRTTIHIVENHANCEH B VB R I I -179elebsiranPEG-IFNα ENSUREHBVelebsiranPEGIFNαENRICHBRII-179elebsiranPEG-IFNαHBVEOTHBsAgHBVHCCHDVHIVC3 MDR/XDR mRNARNARNADNANCENRTIHIVAIDSARTNRTTIPEG-IFNααPK20216302026630RNA0.000005siRNAR N AR N ARNARNA FDAVir BiotechnologyVir Biotechnology, Inc.VIR%騰盛博藥Zhi Hong 2026821 ZhiHongMartin J. Murphy Jr.Grace Hui TangGreggHuber Alton